This annual report covers the period from January 1 to December 31, 2018, corresponding with Grifols’ fiscal year. In sections with historical data, figures appear from the last three years (2016-2018), classified by Grifols’ three main divisions (Bioscience, Hospital and Diagnostics) and regions.

For the purposes of this report, Grifols S.A. and its subsidiaries will be considered “Grifols”. The information contained herein includes all subsidiaries. A list of Grifols subsidiaries is available in Appendix I in the Consolidated Financial Statements.

Financial information included in this report comes from the Consolidated Financial Statements of the fiscal year ending on December 31, 2018.

The report addresses the entirety of Grifols’ operations, ranging from procurement (plasma collection and manufacturing processes) to commercial subsidiaries, taking into consideration the following points:

  • Due to the complexity and global reach of Grifols’ operations, the scope of certain quantitative indicators differs from established standards. All exceptions are duly specified.
  • The indicators contained herein were compiled by Grifols. The procedure used to obtain information ensures methodological rigor and historical comparisons.

Chapter 3: Excellence

  • The data provided by Grifols in this section represents its manufacturing activities. All commercial operations are included with the exception of subsidiaries with fewer than 10 employees.  
  • Since most of Grifols’ manufacturing facilities are based in the U.S. and Spain, the environmental information included in this section is classified by division and region: U.S., Spain and Rest of the World (ROW).

Chapter 3: Teamwork

  • Grifols has included figures from the past two years and classified them by gender (male, female), age and region (North America, Europe and ROW) in all cases where historical figures are available. North America includes the U.S. and Canada, while Europe includes the Czech Republic, France, Germany, Ireland, Italy, Poland, Portugal, Spain, Sweden, Switzerland and the United Kingdom.
  • With regard to personnel data, Grifols changed its reporting criteria in 2017, consolidating all U.S.-based employees on leave, including cases of unpaid leave. (In 2016, workforce data does not include employees on leave at Grifols’ U.S. manufacturing facilities).
  • The calculation of the accident rates includes the most significant facilities, excluding investees dedicated to research initiatives.

This report has been prepared in accordance with the GRI Standards: Core option.

Grifols defined the content of this report using GRI standards:

Stakeholder inclusiveness: Grifols maintains an ongoing dialogue with its stakeholders. The group is able to effectively address their expectations and interests by anticipating their needs.

Context of sustainability: Grifols aspire to contribute to economic, environmental and social progress on local, regional and global levels. Its 2018 performance is contextualized within its countries of operation.

Materiality: This report features the corporate issues that had the greatest economic, environmental and social impact, as well as those that could significantly shape stakeholder decisions and opinions.

Completeness: The topics highlighted in this report adequately reflect the group’s most significant social, economic and environmental impacts, and allow stakeholders to assess their effectiveness throughout the 2018 fiscal year.


Deeply aware of the vital role that stakeholders play in its success, Grifols has several communication channels in place in order to ensure an open and fluid dialogue and stay abreast of their needs and expectations. This report serves as yet another platform to offer information to stakeholders in a clear, concise and ethical manner.

Grifols uses a variety of communication channels to interact with its stakeholder groups, including its corporate website. The following table resumes the main platforms. 

The company is also a member of various trade associations, which allows it to stay up to date on the latest trends, best practices and market demands:

  • FENIN: Federación Española de Empresas de Tecnología Sanitaria 
  • MedTech Europe: European Trade Association representing the medical technology industries, Diagnosis and Medical Devices manufacturers. 
  • EURORDIS: non-profit alliance of 851 rare disease patient organisations from 70 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe. 
  • The United States-Spain Council: an organization in which the US and Spanish leaders promote stronger ties between two countries 
  • EUCOPE: Trade Association representing Small to Medium-Sized Companies Active in Pharmaceuticals & Medical Technologies in Europe 
  • PPTA: Plasma Protein Therapeutics Association 
  • ASEBIO: Asociación Española de Bioempresas 
  • American Chamber of Commerce in Spain 
  • AEF: Asociación Española de Farmacología 
  • AES: Asociación de la Economía de la Salud 
  • SESPAS: Sociedad Española de Salud Pública y Administración Sanitaria 
  • SEFH: Sociedad Española de Farmacia Hospitalaria 
  • SIGRE: Sistema Integrado de Gestión de Residuos de la Industria Farmacéutica 
  • ISPE: International Society for Pharmaceutical Engineering 
  • WHC: Wildlife Habitat Council 
  • ESI: Environmental Stewardship Initiative of the North Carolina Department of Environmental and Natural Resources 
  • ACS: American Chemical Society 
  • Farmafluid: Asociación Española de Laboratorios Farmacéuticos de Fluidoterapia y Nutrición Parenteral 
  • National Health Council (EEUU) 
  • Biotechnology Innovation Organization (BIO) 
  • AENE: Asociación Española de Fabricantes y Distribuidores de Productos de Nutrición Enteral 
  • SENPE: Sociedad Española de Nutrición Parenteral y Enteral


In accordance with the principles established in the GRI 101 Standard, the basis of this report stems from a materiality analysis developed with the guidance of an independent outside firm. It aims to identify the economic, environmental and social impacts of Grifols’ value chain and their influence on stakeholder decisions.


The process of identifying material topics includes the analysis of industry trends and key pressures, as well as the analysis of issues considered relevant by stakeholders.


After identifying the material issues, these were prioritized using several different sources:

  • Identification of sustainability issues that are critical to other groups and companies whose activities are similar to Grifols.
  • Analysis of industry-specific media outlets, social networks and press releases.
  • Industry publications created by analysts and opinion leaders. 
  • Interview with senior decision-makers to understand the group’s priorities and validate core initiatives.

As a result of this process, Grifols identified 18 material issues that form the basis of this report, which are represented in the following table:

We use own and third-party cookies to improve our services, provide faster access to them and personalize them by analyzing your browsing habits. If you continue to browse, we consider that you accept their use. You can obtain more information in our Cookies Policy. Accept